Association of Preoperative Opioid Use and Postoperative Opioid Requirement in Revision Total Knee Arthroplasty

翻修全膝关节置换术中术前阿片类药物使用与术后阿片类药物需求的相关性

阅读:1

Abstract

Purpose The characterization of opioid usage in revision total knee arthroplasty (rTKA) remains incomplete. This study aimed to evaluate postoperative opioid consumption, measured in morphine milligram equivalents (MME), as well as hospital length of stay and discharge destinations such as home versus skilled nursing facility following revision TKA. Methods Patients who underwent rTKA between 2010 and 2018 were assessed for preoperative opioid use and monitored for 24 months postoperatively. Patients were stratified into opioid-naïve or opioid-tolerant categories. Demographic data were collected, and opioid prescriptions and average MME were compared between the two groups. Results Out of 173 patients who underwent rTKA, 91 (53%) were categorized as opioid-tolerant, with an average preoperative MME of 23.5 mg/day. Postoperatively, opioid-tolerant patients exhibited higher daily MME at 3 and 6 months and were more likely to receive opioid prescriptions at 6 and 12 months. Additionally, the opioid-tolerant group experienced a significantly prolonged postoperative hospital stay at 4.82 days versus 3.78 days (p=0.004) and were more inclined to be discharged to a skilled nursing facility (rather than home) compared to the opioid-naïve group, at 40.7% versus 18.3% (p=0.004). Conclusions Opioid-tolerant patients demonstrated elevated postoperative MME requirements, longer recovery periods, and an increased likelihood of skilled nursing facility discharge, underscoring the challenges associated with opioid tolerance in the post-rTKA setting. Both groups showed a reduction in opioid usage at 3 months postoperatively, reaching a plateau at 6 months. These insights can inform revision surgeons in patient counseling and managing expectations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。